Safety Profile Overview
IL-4/IL-13 inhibitor for atopic dermatitis, asthma, and other type 2 inflammatory conditions. One of the fastest-growing biologics globally.
Generic Name
dupilumab
Brand Names
Dupixent
Therapeutic Class
IL-4/IL-13 Inhibitor
Manufacturer
Regeneron/Sanofi
What Pharma Signal Tracks for Dupixent
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Dupixent, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Dupixent products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Dupixent Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Dupixent.
curl "https://api.pharma-signal.com/drug/safety/dupixent" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Dupixent against other IL-4/IL-13 Inhibitor drugs, or explore the full manufacturer portfolio for Regeneron/Sanofi.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Dupixent ranks within IL-4/IL-13 Inhibitor on serious event rates.
- Company portfolio risk — View all drugs from Regeneron/Sanofi with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.